Bafna Pharmaceuticals Ltd vs Jenburkt Pharmaceuticals Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 05, 2026

Key Highlights

The Latest Trading Price of Bafna Pharmaceuticals Ltd is ₹ 131.85 as of 05 May 15:30 . The P/E Ratio of Bafna Pharmaceuticals Ltd changed from 55.8 on March 2021 to 42.6 on March 2025 . This represents a CAGR of -5.26% over 5 yearsThe P/E Ratio of Jenburkt Pharmaceuticals Ltd changed from 11.1 on March 2021 to 13.9 on March 2025 . This represents a CAGR of 4.60% over 5 years The Market Cap of Bafna Pharmaceuticals Ltd changed from ₹ 324.8 crore on March 2021 to ₹ 177.42 crore on March 2025 . This represents a CAGR of -11.39% over 5 yearsThe Market Cap of Jenburkt Pharmaceuticals Ltd changed from ₹ 182.84 crore on March 2021 to ₹ 446.49 crore on March 2025 . This represents a CAGR of 19.55% over 5 years The revenue of Bafna Pharmaceuticals Ltd for the Mar '26 is ₹ 0 crore as compare to the Dec '25 revenue of ₹ 39.51 crore. This represent the decline of -100% The revenue of Jenburkt Pharmaceuticals Ltd for the Mar '26 is ₹ 48.98 crore as compare to the Dec '25 revenue of ₹ 44.84 crore. This represent the growth of 9.23% The ebitda of Bafna Pharmaceuticals Ltd for the Mar '26 is ₹ 0 crore as compare to the Dec '25 ebitda of ₹ 4.27 crore. This represent the decline of -100% The ebitda of Jenburkt Pharmaceuticals Ltd for the Mar '26 is ₹ 14.65 crore as compare to the Dec '25 ebitda of ₹ 9.24 crore. This represent the growth of 58.55% The net profit of Bafna Pharmaceuticals Ltd changed from ₹ -0.72 crore to ₹ 0 crore over 8 quarters. This represents a CAGR of -100.00% The net profit of Jenburkt Pharmaceuticals Ltd changed from ₹ 7.42 crore to ₹ 10.85 crore over 8 quarters. This represents a CAGR of 20.92% The Dividend Payout of Bafna Pharmaceuticals Ltd changed from 0 % on March 2021 to 0 % on March 2025 . This represents a CAGR of 0.0% over 5 yearsThe Dividend Payout of Jenburkt Pharmaceuticals Ltd changed from 28.37 % on March 2021 to 24.76 % on March 2025 . This represents a CAGR of -2.69% over 5 years .

About Bafna Pharmaceuticals Ltd

Bafna Pharmaceuticals Limited (BPL) was started as a proprietary concern in 1981 by Mr. Bafna Mahaveer Chand in the name of Bafna Pharmaceutical and is engaged in the manufacturing of pharmaceutical formulations of Betalactum and Non Betalactum products.
The first manufacturing unit was set up at Madhavaram (Chennai) during October 1984 for manufacture of tablets with an installed capacity of 420 lacs tablets p.a.
Subsequently the capsule line was added during 1987 with a capacity of 300 lacs capsule p.a. and then liquid line with an installed capacity of 45000 lts p.a was added in 1990. Bafna Pharmaceuticals, incorporated in 1995, had acquired the entire business of the proprietary concern.
During the year 2001, the company constructed a separate block at Madhavaram for manufacturing Betalactum products.

About Jenburkt Pharmaceuticals Ltd

Jenburkt Pharmaceuticals Limited, incorporated in 1985, was formed a joint venture to diversify into the healthcare and pharmaceutical industry, by Bhuta family.
The Company is engaged in manufacturing and marketing of speciality and high quality pharmaceutical formulations and healthcare products. Presently, the Company manufactures and markets pharmaceutical formulations in India and internationally across 13 countries.
It has more than 1,000 stockists and their reach extends to 400,000+ pharmacies across the globe.
The organisation caters to government, semi-government institutions, missionary hospitals, public sector enterprises, etc. Apart from this. the Company operate manufacturing plant at Sihor-Gujarat, approved as per W.H.O (World Health Organisation) guidelines with current Good Manufacturing Practices (GMP) requirements.

FAQs for the comparison of Bafna Pharmaceuticals Ltd and Jenburkt Pharmaceuticals Ltd

Which company has a larger market capitalization, Bafna Pharmaceuticals Ltd or Jenburkt Pharmaceuticals Ltd?

Market cap of Bafna Pharmaceuticals Ltd is 311 Cr while Market cap of Jenburkt Pharmaceuticals Ltd is 474 Cr

What are the key factors driving the stock performance of Bafna Pharmaceuticals Ltd and Jenburkt Pharmaceuticals Ltd?

The stock performance of Bafna Pharmaceuticals Ltd and Jenburkt Pharmaceuticals Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Bafna Pharmaceuticals Ltd and Jenburkt Pharmaceuticals Ltd?

As of May 5, 2026, the Bafna Pharmaceuticals Ltd stock price is INR ₹131.85. On the other hand, Jenburkt Pharmaceuticals Ltd stock price is INR ₹1074.5.

How do dividend payouts of Bafna Pharmaceuticals Ltd and Jenburkt Pharmaceuticals Ltd compare?

To compare the dividend payouts of Bafna Pharmaceuticals Ltd and Jenburkt Pharmaceuticals Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.